phrykt

Macrogenics Inc (MGNX): who owns it and who trades it

As of Nov 16, 2026, MGNX insiders reported 1 open-market sale worth $129K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jeffrey Stuart Peters (Vice president), with $129K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Macrogenics

From the latest filings

Overall: about as much buying as selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MGNX

122 funds and institutions reported MGNX shares worth $226M at the end of Q2 2026, about 77% of the company. The largest holder is Armistice Capital, LLC with 7.9%.

Funds and institutions (13F) 77%Everyone else 23%

10 largest owners, by share of the company

Armistice Capital, LLC7.9%
BlackRock, Inc.7.4%
Vanguard Capital Management LLC4.2%
Renaissance Technologies LLC4.1%
Acadian Asset Management LLC4.0%
Bank of America Corp3.9%
Two Sigma Investments, LP3.9%
Millennium Management LLC3.7%
Wasatch Advisors LP3.2%
Ra Capital Management, L.P.2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Armistice Capital, LLC5.01M7.88%$23.1M-17%
BlackRock, Inc.4.68M7.36%$21.6M+302%
Vanguard Capital Management LLC2.66M4.18%$12.3M+0%
Renaissance Technologies LLC2.63M4.14%$12.2M-11%
Acadian Asset Management LLC2.54M4.00%$11.7M-0%
Bank of America Corp2.49M3.92%$11.5M+4%
Two Sigma Investments, LP2.47M3.88%$11.4M-2%
Millennium Management LLC2.37M3.74%$11M-15%
Wasatch Advisors LP2.02M3.18%$9.3M+29%
Ra Capital Management, L.P.1.86M2.93%$8.6MNo change
Vanguard Portfolio Management LLC1.82M2.86%$8.4M+51%
Mackenzie Financial Corp1.64M2.58%$7.6M+175%
Marshall Wace, LLP1.62M2.54%$7.5M-20%
Geode Capital Management, LLC1.58M2.48%$7.3M+126%
Affinity Asset Advisors, LLC1.22M1.91%$5.6M+143%
D. E. Shaw & Co., Inc.1.06M1.67%$4.9M+0%
Jacobs Levy Equity Management, Inc1.00M1.58%$4.6M+127%
Connor, Clark & Lunn Investment Management Ltd.1.00M1.57%$4.6M+15%
State Street Corp863,6631.36%$4M+194%
Goldman Sachs Group Inc558,0010.88%$2.6M+104%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MGNX insiders reported $0 of open-market purchases and $129K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$129K
1 trades, 1 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Aug 19, 2026
Filed Aug 20, 2026

Purchases and sales by month

$129K$129KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 19, 2026Jeffrey Stuart PetersVice presidentSale plan31,105$4.15$129KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jeffrey Stuart PetersSenior VP, GC, and Secretary–$129KAug 19, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MGNX short interest

Moderate short interest. 7.8% of MGNX shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went up 1%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.95M MGNX shares were sold short, 7.8% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 3.9 trading days (days to cover).

Shares short, % of all shares

7.77%May 15Oct 3012.1%

Days to cover

3.9May 15Oct 3019.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.95M7.77%-2%1.28M3.9
Oct 15, 20265.06M7.94%-28%618,6398.2
Sep 30, 20267.04M11.05%+0%645,90910.9
Sep 15, 20267.03M11.04%-1%447,17615.7
Aug 31, 20267.12M11.19%-2%413,11117.2
Aug 14, 20267.26M11.39%-1%602,63012.0
Jul 31, 20267.34M11.55%+29%786,4979.3
Jul 15, 20265.69M8.95%-14%836,6636.8
Jun 30, 20266.63M10.43%+38%1.92M3.5
Jun 15, 20264.79M7.54%-4%562,0758.5
May 29, 20264.98M7.83%+2%951,7215.2
May 15, 20264.88M7.67%+66%1.96M2.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Macrogenics company events

Macrogenics filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026LeadershipThe Board of Directors of MacroGenics, Inc., upon the recommendation of the Nominating and Governance Committee of the Board, approved an increase in the size of the Board from ten to eleven members. Filing
  2. Oct 23, 2026AnnouncementMacroGenics, Inc. issued a press release announcing interim data related to its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumors. Filing
  3. Aug 13, 2026ResultsReleased financial results. Filing
  4. Jul 23, 2026AnnouncementOn July 23, 2026, MacroGenics, Inc. issued a press release providing a clinical update on its ongoing Phase 1 study of MGC026. Filing
  5. Jul 8, 2026LeadershipKaren Ferrante, M.D. provided notice to the board of directors of MacroGenics, Inc. of her decision to resign from the Board, effective September 1, 2026. Filing
  6. Jul 7, 2026DealMacroGenics, Inc. completed the previously announced sale of certain assets and liabilities related to its GMP manufacturing operations, including its CDMO business conducted by the Company at its manufacturing facility located at 9704 Medical Center Drive, Rockville, Maryland and related warehouse… Filing
  7. May 20, 2026VoteReported shareholder vote results. Filing
  8. May 13, 2026ResultsReleased financial results. Filing
  9. May 12, 2026AgreementMacroGenics, Inc., a Delaware corporation, entered into an Asset Purchase Agreement with Bora Pharmaceuticals Co., Ltd., a company organized under the laws of Taiwan, and Bora Biologics USA, LLC, a Delaware limited liability company, pursuant to which the Company agreed to sell to the Purchaser… Filing
  10. May 4, 2026AgreementMacroGenics, Inc. and an entity affiliated with Sagard Healthcare Partners entered into a First Amendment to the Purchase and Sale Agreement, dated as of June 9, 2025, pursuant to which the Company previously sold to Sagard its right to receive royalties on global net sales of ZYNYZ… Filing
  11. Apr 8, 2026AnnouncementMacroGenics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has removed the partial clinical hold on the Company’s Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers. Filing
  12. Mar 9, 2026ResultsReleased financial results. Filing
  13. Mar 2, 2026AnnouncementDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  14. Feb 24, 2026AnnouncementMacroGenics, Inc. issued a press release announcing that the U.S. Food and Drug Administration has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers. Filing
  15. Nov 20, 2025LeadershipMacroGenics, Inc. and Stephen Eck, M.D., Ph.D., Senior Vice President, Clinical Development and Chief Medical Officer of the Company, mutually agreed that Dr. Eck would depart the Company, effective as of December 31, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Macrogenics financials

Famous investors that hold MGNX

5 of the 50 well-known investors we track reported holding MGNX in their latest 13F filing. The largest position is Jim Simons's, worth $8.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.18M$8.4M0.0%-17%
Israel Englander · Millennium ManagementQ3 20261.20M$4.6M0.0%-50%
Ken Griffin · Citadel AdvisorsQ3 2026585,493$2.3M0.0%+226%
Steve Cohen · Point72 Asset ManagementQ3 2026100,870$389K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202690,676$350K0.0%+455%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named MGNX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G/A9.4%
Nov 16, 2026Armistice Capital, LLC13G/A9.4%

Questions about Macrogenics Inc (MGNX) stock

Who owns the most MGNX stock?

The largest reported owner of Macrogenics Inc (MGNX) is Armistice Capital, LLC, with 7.9% of the company. In total, 122 funds and institutions reported holding MGNX at the end of Q2 2026, together about 77% of the shares. See the largest owners.

Are MGNX insiders buying or selling?

In the last 12 months, MGNX insiders reported no open-market purchases and 1 sale worth $129K. The latest trade was on Aug 19, 2026. See every trade.

What is the short interest in MGNX?

As of Oct 30, 2026, 4.95M MGNX shares were sold short, 7.8% of the shares outstanding, down 2.2% from the report before. At the average daily volume of 1.28M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.

Which famous investors hold MGNX?

5 of the 50 well-known investors we track reported MGNX in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $8.4M. See all holders.

Executive pay

Macrogenics's chief executive was paid a total of $6.4M for the year ended Dec 31, 2024, up 73% from $3.7M the year before. In the last 12 months, Macrogenics's executives and directors bought no stock on the open market and sold $129K.

Chief executive, total pay$6.4MYear ended Dec 31, 2024. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.5MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.